Thyroid Function Before, During, and After COVID-19.
Adult
Aged
Aged, 80 and over
COVID-19
/ complications
Cohort Studies
Comorbidity
Female
Follow-Up Studies
Humans
Male
Middle Aged
Risk Factors
SARS-CoV-2
/ physiology
Thyroid Diseases
/ blood
Thyroid Function Tests
Thyroid Gland
/ physiology
Thyrotropin
/ blood
Thyroxine
/ blood
Time Factors
Triiodothyronine
/ blood
COVID-19
SARS-CoV-2
thyroid function
thyroid gland
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
23 01 2021
23 01 2021
Historique:
received:
24
09
2020
pubmed:
13
11
2020
medline:
28
1
2021
entrez:
12
11
2020
Statut:
ppublish
Résumé
The effects of COVID-19 on the thyroid axis remain uncertain. Recent evidence has been conflicting, with both thyrotoxicosis and suppression of thyroid function reported. We aimed to detail the acute effects of COVID-19 on thyroid function and determine if these effects persisted on recovery from COVID-19. A cohort observational study was conducted. Adult patients admitted to Imperial College Healthcare National Health Service Trust, London, UK, with suspected COVID-19 between March 9 to April 22, 2020, were included, excluding those with preexisting thyroid disease and those missing either free thyroxine (FT4) or thyrotropin (TSH) measurements. Of 456 patients, 334 had COVID-19 and 122 did not. TSH and FT4 measurements were recorded at admission, and where available, in 2019 and at COVID-19 follow-up. Most patients (86.6%) presenting with COVID-19 were euthyroid, with none presenting with overt thyrotoxicosis. Patients with COVID-19 had a lower admission TSH and FT4 compared to those without COVID-19. In the COVID-19 patients with matching baseline thyroid function tests from 2019 (n = 185 for TSH and 104 for FT4), TSH and FT4 both were reduced at admission compared to baseline. In a complete case analysis of COVID-19 patients with TSH measurements at follow-up, admission, and baseline (n = 55), TSH was seen to recover to baseline at follow-up. Most patients with COVID-19 present with euthyroidism. We observed mild reductions in TSH and FT4 in keeping with a nonthyroidal illness syndrome. Furthermore, in survivors of COVID-19, thyroid function tests at follow-up returned to baseline.
Identifiants
pubmed: 33180932
pii: 5979483
doi: 10.1210/clinem/dgaa830
pmc: PMC7823247
doi:
Substances chimiques
Triiodothyronine
06LU7C9H1V
Thyrotropin
9002-71-5
Thyroxine
Q51BO43MG4
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e803-e811Subventions
Organisme : Medical Research Council
ID : MR/T006242/1
Pays : United Kingdom
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society.
Références
Lancet Diabetes Endocrinol. 2020 Aug;8(8):659-660
pubmed: 32563278
J Clin Endocrinol Metab. 2000 Apr;85(4):1388-93
pubmed: 10770171
Biochem Cell Biol. 2010 Aug;88(4):723-30
pubmed: 20651845
J Pathol. 2004 Jun;203(2):622-30
pubmed: 15141376
Clin Infect Dis. 2021 Dec 6;73(11):e4047-e4057
pubmed: 32766823
Endocrinology. 2020 Sep 1;161(9):
pubmed: 32652001
Int J Antimicrob Agents. 2020 May;55(5):105951
pubmed: 32234466
Hum Pathol. 2007 Jan;38(1):95-102
pubmed: 16996569
Eur J Endocrinol. 2020 Oct;183(4):381-387
pubmed: 32698147
Thyroid. 2021 Jan;31(1):8-11
pubmed: 32600165
J Clin Endocrinol Metab. 2020 Oct 1;105(10):
pubmed: 32780854
Lancet Diabetes Endocrinol. 2020 Sep;8(9):739-741
pubmed: 32738929
Thyroid. 2014 Oct;24(10):1456-65
pubmed: 24845024